Recent Development News: Q3 – 2017

Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced the appointment of Robert R. Ruffolo, Jr., Ph.D., to its Board of Directors, effective … Continue reading

Posted in Recent Development News: Q3 - 2017, Recent Developments | Comments Off

Edge Therapeutics Announces Commercial Supply Agreement for EG- 1962 with Oakwood Laboratories

Edge Therapeutics, Inc.(Nasdaq:EDGE) today announced that it has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories for the commercial manufacturing of EG-1962 for initial product launch and thereafter. EG-1962, an orphan drug and … Continue reading

Posted in Recent Development News: Q3 - 2017, Recent Developments | Comments Off